AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02276807 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation
Description: This is a 4-session individual workshop using behavioral activation techniques.
Study NCT02276807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
Study NCT04376931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Solution
Description: Iscador®P: fermented aqueous extract of mistletoe grown on pine tree (Viscum album L. subspecies austriacum (Wiesb.) Vollmann), licensed for subcutaneous (SC) application in Switzerland, Germany, Austria, Sweden, and South Korea in dosages up to 20 mg.
Study NCT02361606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An Internet Cognitive-Behavioral Intervention
Description: We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
Study NCT02460146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXA-10
Description: CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
Study NCT02460146 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CXA-10 placebo
Description: The placebo contains olive oil with BHT (0.08% to 0.10%).
Study NCT01819805 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
Study NCT03901742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein-enriched nutrition
Description: Protein-enriched enteral nutrition with a polymeric infant formula
Study NCT03901742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Protein-enriched Nutrition
Description: High protein-enriched enteral nutrition with a polymeric infant formula plus a protein supplement
Study NCT03901742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Enteral Nutrition
Description: Cow's milk based infant formula.
Study NCT01679756 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic right hemicolectomy for cancer
Description: After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
Study NCT01679756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy for cancer
Description: After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
Study NCT03273933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DragONE
Description: The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
Study NCT03273933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DragONE
Description: The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
Study NCT03273933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartOne
Description: A little portable spirometer connected to DragONE allows daily PEF monitoring.
Study NCT03037242 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transtibial pullout technique
Description: Evaluating radographs
Study NCT03316053 — intervention group
Intervention type: OTHER
Intervention: Tissue sample for genetic testing
Description: Tissue sample to be obtained during routine endoscopy
Study NCT04312113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose derived, autologous mesenchymal stem cells
Description: Fat tissue will be enzymatically treated and cells will be cultured until a sufficient number are obtained for the treatment protocol.
Study NCT04205513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medly
Description: Medly is a mobile phone-based telemonitoring system that enables patients with heart failure to take clinically relevant physiological measurements with wireless home medical devices and answer symptom questions on the mobile phone. The measurements are automatically and wirelessly transmitted to the mobile phone and then to a data server.
Study NCT03907072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WVE-210201 (suvodirsen)
Description: WVE-210201 is a stereopure antisense oligonucleotide (ASO)
Study NCT03907072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffered saline solution
Study NCT04168775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Home PIFR monitoring with InCheck Dial
Description: The In-Check G16 DIAL® (Alliance Tech Medical, Granbury TX) is a simple hand-held device that measures PIFR via a brief inspiratory maneuver.
Study NCT01176422 — intervention group
Intervention type: GENETIC
Intervention: Blood sample
Description: Blood samples will be collected before and after treatment completion.
Study NCT04531436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief mindful eating intervention
Description: Over the 9-week intervention, participants will be introduced to various mindful eating and intuitive eating practices which are aimed at reducing overeating and facilitating weight loss. Each session will focus on one simple, evidence-based message, aimed at modifying a current weight-relevant eating behavior of the patient. The intervention will focus on two key elements: (1) the mindful awareness of body cues (intuitive eating) and (2) the mindful awareness of external cues (mindful eating).
Study NCT04659356 — intervention group
Intervention type: OTHER
Intervention: Patients admitted in Intensive Care Units
Description: Data will be collected computerized patient records by the clinicians in charge of the patient.
Study NCT01381601 — intervention group
Intervention type: DRUG
Intervention: Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
Description: Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
Study NCT03811899 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: The purpose of this study is to determine whether HG SOC are 18F-DCFPyL (=GCP-II)-avid and to compare the performance of this PET to CT and findings at time of surgery.
Study NCT04518826 — intervention group
Intervention type: DEVICE
Intervention: fractional flow reserve
Description: FFR is a physiological functional parameter indicating the severity of ischemic myocardium perfused by a diseased coronary artery. It is measured by a pressure wire placed in the coronary artery and calculated by the ratio of pressures distal and proximal to the stenosis.
Study NCT00817752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha
Description: Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
Study NCT01721668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Supported Rehabilitation
Description: Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
Study NCT01721668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Upper Extremity Therapy
Description: -GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
Study NCT04576585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lexicon training
Description: Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
Study NCT04576585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lexicon training
Description: Participants will receive training on the lexicon of appetite on up to 3 days during the training week. This will entail reading written definitions, watching an instructional video, eating exercises and completing training exams demonstrating they understand the distinctions between appetitive terms (hunger, desire to eat, fullness, and prospective consumption). The training will require about 30 minutes to complete. To ensure the success of training, participants must verbally describe the definitions of the outcome sensations to a member of the research team and complete a written quiz with at least 90 % correct responses. Failure to satisfactorily convey understanding of the concepts will result in an offer to repeat the training 2 more times or be rejected from the study.
Study NCT00568399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium thiosulfate
Description: sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
Study NCT02604134 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prophylaxis
Description: A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
Study NCT02604134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fluoride varnish
Description: Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
Study NCT02604134 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Silver Nitrate
Description: a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
Study NCT01012700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hiltonol (poly ICLC)
Description: 2 mg administered subcutaneously or intranasally to healthy volunteers
Study NCT04287673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation involving strongly the trunk
Description: The Rehabilitation involving strongly the trunk (RIST) leaded by a physiotherapist was based on exercises in different postures performed by the child each day that strongly involve the trunk to cope with balance.
Study NCT02781636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: StimGuard Protect System
Description: Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
Study NCT01421784 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cine MRI
Description: Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
Study NCT01964586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
Study NCT01964586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
Study NCT01964586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: 12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
Study NCT03367091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ekso GT gait training with high swing assistance
Description: Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high assistance
Study NCT03367091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ekso GT gait training with neutral swing assistance
Description: Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at neutral
Study NCT03367091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ekso GT gait training with high swing resistance
Description: Participant will walk for 20-minutes in the Ekso GT SmartAssist with the swing assistance set at high resistance
Study NCT00273715 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Surgical wound closure techniques
Description: Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
Study NCT00273715 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Surgical wound closure techniques (Comparator)
Description: Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
Study NCT00931515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuBac
Description: NuBac device implanted at the L4/5 level.
Study NCT00348556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nesiritide
Description: Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
Study NCT04514575 — intervention group
Intervention type: BIOLOGICAL
Intervention: Plasma transfusion
Description: Transfusion of allogeneic fresh frozen plasma or cryoprecipitate
Study NCT05655130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intraoperative 10 mg IV Dose
Study NCT05655130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: The oral methylprednisolone taper course will begin on the day of surgery and will taper as noted below:~Day 1: 24 mg orally (8 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 2: 20 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 8 mg at bedtime) Day 3: 16 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg after dinner; 4 mg at bedtime) Day 4: 12 mg orally (4 mg before breakfast; 4 mg after lunch; 4 mg at bedtime) Day 5: 8 mg orally (4 mg before breakfast; 4 mg at bedtime) Day 6: 4 mg orally (4 mg before breakfast)
Study NCT00931515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prodisc-L
Description: Prodisc-L implanted at the L4/5 level.
Study NCT04129736 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Teriflunomide 14 MG
Description: Blood and cerebrospinal fluid is obtained from teriflunomide treated patients with multiple sclerosis
Study NCT01294319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Study NCT03555656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Repeated intervention
Description: Repetition twice a year of a 2-h group session educating patients at foot hygiene and ulcer prevention
Study NCT03555656 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single session
Description: Single 2-h group session educating patients at foot hygiene and ulcer prevention
Study NCT01294319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01294319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Study NCT01294319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined
Study NCT01294319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT01957410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
Study NCT01957410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
Study NCT03563170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA
Study NCT03563170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
Study NCT04012866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: The aerobic exercise program using progressive resistive stationary bicycle training which will contain warm-up, resistive physical exercise, and cool-down. The training resistance will increase with improvement of participants' performance.
Study NCT04012866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: The computerized cognitive training program will be implemented with the brainHQ to target abilities of visuospatial processing, attention, memory, and executive function. The level of the training program will become more difficult with progress in participants' targeted cognitive abilities.
Study NCT04012866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control training
Description: The Control training will receive an intervention including combinations of non-aerobic physical activities and unstructured mental activities.
Study NCT02319798 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone consultations
Description: Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
Study NCT02319798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: face-to-face consultations
Description: Those randomized to face-to-face follow up will attend their appointments in hospital
Study NCT04645628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI examination
Description: All subjects (healthy subjects and patients) will have an MRI examination with optimized sequences
Study NCT04966442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GrandAides
Description: Enhanced post acute care for patients recently admitted for congestive heart failure
Study NCT03493204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal delivery
Description: The food will be pre-packaged for storage and patient will prepare these meals at home
Study NCT03493204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard pamphlet with Dietary Advice
Description: Explains how to maintain a low-sodium diet
Study NCT01917799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 75mg tab of LDA once daily for 7 months
Study NCT01917799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 75mg tab of LDA once daily for 7 months
Study NCT01917799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: 0.4 mL/day of the Enoxaparin
Study NCT04774029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Basivertebral nerve block
Description: Temporary intraosseous basivertebral nerve block using lidocaine